Last reviewed · How we verify
IMOVAX Polio™: Inactivated Poliomyelitis Vaccine
IMOVAX Polio™: Inactivated Poliomyelitis Vaccine is a Inactivated viral vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently FDA-approved for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3. Also known as: IMOVAX Polio™.
IMOVAX Polio stimulates the immune system to produce antibodies against all three poliovirus types by introducing inactivated (killed) poliovirus particles.
IMOVAX Polio stimulates the immune system to produce antibodies against all three poliovirus types by introducing inactivated (killed) poliovirus particles. Used for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3.
At a glance
| Generic name | IMOVAX Polio™: Inactivated Poliomyelitis Vaccine |
|---|---|
| Also known as | IMOVAX Polio™ |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | Inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains chemically inactivated poliovirus serotypes 1, 2, and 3, which cannot cause disease but trigger a humoral immune response. B cells recognize the viral antigens and produce neutralizing antibodies that protect against infection if the vaccinated person is exposed to wild-type poliovirus. This provides long-lasting immunity through antibody-mediated protection without the risk of vaccine-derived poliovirus.
Approved indications
- Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (PHASE3)
- Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults (PHASE1)
- Safety of Imovax Polio in Chinese Infants and Children (PHASE3)
- Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV (PHASE3)
- A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China (PHASE4)
- A Study of the Safety of IMOVAX Polio™ in China (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMOVAX Polio™: Inactivated Poliomyelitis Vaccine CI brief — competitive landscape report
- IMOVAX Polio™: Inactivated Poliomyelitis Vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about IMOVAX Polio™: Inactivated Poliomyelitis Vaccine
What is IMOVAX Polio™: Inactivated Poliomyelitis Vaccine?
How does IMOVAX Polio™: Inactivated Poliomyelitis Vaccine work?
What is IMOVAX Polio™: Inactivated Poliomyelitis Vaccine used for?
Who makes IMOVAX Polio™: Inactivated Poliomyelitis Vaccine?
Is IMOVAX Polio™: Inactivated Poliomyelitis Vaccine also known as anything else?
What drug class is IMOVAX Polio™: Inactivated Poliomyelitis Vaccine in?
What development phase is IMOVAX Polio™: Inactivated Poliomyelitis Vaccine in?
What are the side effects of IMOVAX Polio™: Inactivated Poliomyelitis Vaccine?
Related
- Drug class: All Inactivated viral vaccine drugs
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3
- Also known as: IMOVAX Polio™
- Compare: IMOVAX Polio™: Inactivated Poliomyelitis Vaccine vs similar drugs
- Pricing: IMOVAX Polio™: Inactivated Poliomyelitis Vaccine cost, discount & access